The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist.

@article{Tang2008ThePD,
  title={The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist.},
  author={Hua Lucy Tang and Jenny Ying-Lin Lu and Xiaomu Zheng and Yuhua Yang and Jeff D. Reagan},
  journal={Biochemical and biophysical research communications},
  year={2008},
  volume={375 4},
  pages={562-5}
}
Nicotinic acid has been used for several decades to treat dyslipidemia. In mice, the lipid-lowing effect of nicotinic acid is mediated by the Gi coupled receptor PUMA-G. In humans, high (GPR109A) and low (GPR109B) affinity nicotinic acid receptors have been characterized. Here we identify monomethylfumarate as a GPR109A agonist. Monomethylfumarate is the active metabolite of the psoriasis drug Fumaderm. We show that monomethylfumarate activates GPR109A in a calcium based aequorin assay, cAMP… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 35 extracted citations

Similar Papers

Loading similar papers…